Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials
| العنوان: | Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials |
|---|---|
| المؤلفون: | Bradford C. Dickerson, David J. Irwin, Eliana Marisa Ramos, Joel H. Kramer, Adam L. Boxer, Gink-Yuek Hsiung, Kamalini G. Ranasinghe, David S. Knopman, Yann Cobigo, John Kornak, Leah Forsberg, Julie Fields, Diana R. Kerwin, Brian S. Appleby, Murray Grossman, Jamie Fong, Daniel I. Kaufer, Jeremy Syrjanen, Rosa Rademakers, Ian R. A. Mackenzie, Brad F. Boeve, Kejal Kantarci, Bruce L. Miller, Neill R. Graff-Radford, Gianina Toller, Nupur Ghoshal, Katya Rascovsky, Sandra Weintraub, Katherine P. Rankin, Howard J. Rosen, Erik D. Roberson, Adam M. Staffaroni, Irene Litvan, Kimiko Domoto-Reilly, Edward D. Huey, Carmela Tartaglia, Mario F. Mendez, Hilary Heuer, Danielle Brushaber, Giovanni Coppola |
| المساهمون: | ARTFL/LEFFTDS Consortium |
| المصدر: | Neurology |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Asymptomatic, Article, 03 medical and health sciences, 0302 clinical medicine, Atrophy, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Longitudinal Studies, Biology, Aged, Clinical Trials as Topic, Socioemotional selectivity theory, business.industry, Self-Management, Reproducibility of Results, Caregiver burden, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Clinical trial, Facial Expression, Expressed Emotion, 030104 developmental biology, Caregivers, Frontotemporal Dementia, Self-monitoring, Female, Neurology (clinical), Human medicine, medicine.symptom, business, 030217 neurology & neurosurgery, Frontotemporal dementia |
| الوصف: | ObjectiveTo investigate whether the Revised Self-Monitoring Scale (RSMS), an informant measure of socioemotional sensitivity, is a potential clinical endpoint for treatment trials for patients with behavioral variant frontotemporal dementia (bvFTD).MethodsWe investigated whether RSMS informant ratings reflected disease severity in 475 participants (71 bvFTD mutation+, 154 bvFTD mutation−, 12 behavioral mild cognitive impairment [MCI] mutation+, 98 asymptomatic mutation+, 140 asymptomatic mutation−). In a subset of 62 patients (20 bvFTD mutation+, 35 bvFTD mutation−, 7 MCI mutation+) who had at least 2 time points of T1-weighted images available on the same 3T scanner, we examined longitudinal changes in RSMS score over time and its correspondence to progressive gray matter atrophy.ResultsRSMS score showed a similar pattern in mutation carriers and noncarriers, with significant drops at each stage of progression from asymptomatic to very mild, mild, moderate, and severe disease (F4,48 = 140.10, p < 0.001) and a significant slope of decline over time in patients with bvFTD (p = 0.004, 95% confidence interval [CI] −1.90 to −0.23). More rapid declines on the RSMS corresponded to faster gray matter atrophy predominantly in the salience network (SN), and RSMS score progression best predicted thalamic volume in very mild and mild disease stages of bvFTD. Higher RSMS score predicted more caregiver burden (p < 0.001, 95% CI −0.30 to −0.11).ConclusionsThe RSMS is sensitive to progression of both socioemotional symptoms and SN atrophy in patients with bvFTD and corresponds directly to caregiver burden. The RSMS may be useful in both neurologic practice and clinical trials aiming to treat behavioral symptoms of patients with bvFTD. |
| تدمد: | 1526-632X 0028-3878 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dcc7449f55e5eb9eecf15c04fdd63a5Test https://pubmed.ncbi.nlm.nih.gov/32371446Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6dcc7449f55e5eb9eecf15c04fdd63a5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1526632X 00283878 |
|---|